We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Accurately Measures Serum Hepcidin-25

By LabMedica International staff writers
Posted on 08 Nov 2010
Print article
An enzyme linked immunoassay assay (ELISA) can precisely measure the concentration of hepcidin-25 in serum.

Hepcidin is a key regulator of iron metabolism deficiency has been linked to hemochromatosis and iron overload, while increased concentrations are found in anemia of malignancy and chronic diseases.

Hepcidin-23 is the active form of the protein that binds to the iron transporter ferroportin to cause its degradation. A sandwich ELISA test using two antihepcidin-25 monoclonal antibodies was compared with the liquid chromatography-mass spectrometry (LC-MS) method. One hundred serum samples from healthy volunteers (ages 18–64 years, mean age 37 years) with a broad ethnic range and an equal number of male and females, and 34 serum samples from cancer patients were tested at the Lilly Research Laboratories, (Eli Lilly and Company; Indianapolis, IN, USA).

The sandwich ELISA was highly specific for hepcidin-25, having a limit of quantification of 10 pg/mL. Serum concentrations of hepcidin-25 measured by ELISA correlated with hepcidin-25 concentrations measured by using an independent LC-MS assay. Hepcidin-25 concentrations were increased in 34 patients with cancer (median 54.8 µg/L, 25% - 75% range 23.2 - 93.5 µg/L,) and 76 with rheumatoid arthritis (median 10.6 µg/L, 25% - 75% range 5.9 - 18.4 µg/L,) compared with 100 healthy individuals (median 1.20 µg/L, 25% - 75% range 0.42 - 3.07 µg/L.

This sandwich ELISA could also be used to help diagnose iron deficiency anemia in difficult cases in which it may coexist with anemia of chronic disease. In uncomplicated iron deficiency, hepcidin concentrations would be expected to be quite low, whereas in anemia of chronic disease without coexisting iron deficiency, hepcidin concentrations would be expected to be increased. In patients with anemia of chronic disease, a relatively low serum hepcidin concentration might also indicate the presence of coexisting iron deficiency. The study was published in September 2010 in Clinical Chemistry.

Related Links:

Eli Lilly and Company



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.